Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous Dosing
Overview
Authors
Affiliations
To facilitate subcutaneous dosing, biotherapeutics need to exhibit properties that enable high-concentration formulation and long-term stability in the formulation buffer. For antibody-drug conjugates (ADCs), the introduction of drug-linkers can lead to increased hydrophobicity and higher levels of aggregation, which are both detrimental to the properties required for subcutaneous dosing. Herein we show how the physicochemical properties of ADCs could be controlled through the drug-linker chemistry in combination with prodrug chemistry of the payload, and how optimization of these combinations could afford ADCs with significantly improved solution stability. Key to achieving this optimization is the use of an accelerated stress test performed in a minimal formulation buffer.
Lubaev A, Marvin C, Dombrowski A, Qureshi Z RSC Adv. 2024; 14(40):29184-29188.
PMID: 39285872 PMC: 11403387. DOI: 10.1039/d4ra03725a.
The medicinal chemistry evolution of antibody-drug conjugates.
Hobson A RSC Med Chem. 2024; 15(3):809-831.
PMID: 38516594 PMC: 10953486. DOI: 10.1039/d3md00674c.
Hobson A, Zhu H, Qiu W, Judge R, Longenecker K RSC Med Chem. 2024; 15(3):832-838.
PMID: 38516584 PMC: 10953475. DOI: 10.1039/d3md00540b.
Recent Technological and Intellectual Property Trends in Antibody-Drug Conjugate Research.
Choi Y, Choi Y, Hong S Pharmaceutics. 2024; 16(2).
PMID: 38399275 PMC: 10892729. DOI: 10.3390/pharmaceutics16020221.
Wang L, Hobson A, Fitzgibbons J, Hernandez Jr A, Jia Y, Xu Z RSC Med Chem. 2024; 15(1):355-365.
PMID: 38283215 PMC: 10809321. DOI: 10.1039/d3md00473b.